Financial Data and Key Metrics Changes - For Q2 2025, revenue totaled $70,000 from a research license agreement with Catalent, compared to no revenue in Q2 2024 [9] - Operating expenses decreased to $4,900,000 in Q2 2025 from $5,500,000 in Q2 2024, a reduction of 10.6% [10] - Net losses were $4,700,000 for Q2 2025, down from $5,000,000 in Q2 2024, indicating progress in capital management [11] Business Line Data and Key Metrics Changes - Research and development expenses were approximately $2,300,000 in Q2 2025, down from $2,600,000 in Q2 2024, a decrease of 13.4% [10] - General and administrative expenses were approximately $2,700,000 in Q2 2025, compared to $2,900,000 in Q2 2024, a decrease of 8.1% [10] Market Data and Key Metrics Changes - The company anticipates a data-rich period in the next twelve months with several key milestones on the horizon [6] Company Strategy and Development Direction - The company is focused on developing its proprietary cyclic internalizing RGD peptide product candidate, certepatide, for advanced solid tumors and other difficult-to-treat diseases [12] - Recent collaborations include a research agreement with Catalent and a strategic alliance with GATC Health to enhance drug discovery [24][25] - The company has secured multiple special designations from both the FDA and EMA for certepatide [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of certepatide based on positive preliminary results from ongoing clinical trials [6][28] - The company is preparing for a Phase III trial based on FDA agreement on the protocol, with an expected enrollment of 650 to 900 patients [30] Other Important Information - The company has extended its patent protection for certepatide until March 2040, enhancing its intellectual property portfolio [25] - The company believes available funds will support current operations into 2026 [11] Q&A Session Summary Question: Insights on the ASCEND trial Phase III protocol - Management confirmed a tacit agreement with the FDA on the structure of an open-label Phase III trial, potentially including 650 to 900 patients [30] Question: Expectations on spending and runway extension - Management indicated that spending may see a modest decrease over time, depending on the initiation of the Phase III trial and results from ongoing trials [33] Question: Inclusion of future license revenues in projections - Management clarified that current projections only include a small contribution from the New Jersey sale of NOLs, with no anticipated capital raises included [36] Question: Changes in patent coverage - Management explained that the latest patent recognized specific intellectual property around the composition of matter of certepatide, securing the intellectual property portfolio [38] Question: Comparison of regulatory environments in the US and China - Management stated that it is difficult to compare the two regulatory environments due to the unique relationships Chinese companies have with their authorities [40]

MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Up https://t.co/x30NSJZwz0 https://t.co/x30NSJZwz0 ...

MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Uphttps://t.co/tDHJ5pbUVJ https://t.co/rEWPU9sScs ...

Funding & Collaboration - The Weill Family Foundation donated $100 million to two Bay Area universities for cancer research [1] - The donation aims to advance cancer research and treatment through four specific projects [1]

The complexity of cancer, with its bewildering variety of forms, makes devising treatments difficult. But progress is being made https://t.co/YFuhNoKaxL ...

Philanthropy & Research - The Weill Family Foundation donated $100 million to two Bay Area universities for cancer research [1] - The donation will fund a new cancer hub designed to advance cancer research and treatment [1] Project Focus - The cancer hub will focus on four specific projects [1]

The complexity of cancer, with its bewildering variety of forms, makes devising treatments difficult. But progress is being made https://t.co/sY6axYDRWz ...

The complexity of cancer, with its bewildering variety of forms, makes devising treatments difficult. But progress is being made https://t.co/izST8Pdpe7 ...

A new technique is emerging in the fight against cancer, alongside the mainstays of surgery, chemotherapy and radiotherapy https://t.co/noeFZ0GSVe ...

Healthcare Industry Bottleneck - Clinical trial bottlenecks cause delays in new drugs reaching the market [1] - Two cancer doctors developed AI-enabled technology to accelerate the drug development process [1]